
From: Michael Clarke
Sent: Monday, October 08, 2012 10:21 AM
To: Lynne Baxter
Cc: Nancy Baran
Subject: FW:
Attachments: Document.pdf

Lynne and Nancy,

Please find the signed acknowledgement from Discount Drug.

Michael

Michael R. Clarke
Actavis
973-889-6667
MCLARKE@actavis.com


-----Original Message-----

From: Jill Strang [<mailto:JStrang@discount-drugmart.com>]
Sent: Monday, October 08, 2012 11:24 AM
To: Michael Clarke
Subject: FW:

-----Original Message-----

From: DDM-PHARMACY [<mailto:DDMRX@Discount-Drugmart.com>]
Sent: Monday, October 08, 2012 11:24 AM
To: Jill Strang
Subject:

Please open the attached document. This document was digitally sent to you from Discount Drug Mart. This e-mail transmission may contain information that is proprietary and/or confidential and is intended exclusively for the person (s) to whom it is addressed. Any use, copying, retention or disclosure by any person other than the intended recipient or the intended recipient's designees is strictly prohibited. If you are not the intended recipient or there designee, please notify the sender immediately by return e-mail and delete all copies.



emailed to Lisa Pehlke

10-5-12

think smart medicine

September 21, 2012

Parviz Boodjeh
DISCOUNT DRUG MART
211 Commerce Drive
Medina, OH 44256

Re: Suspicious Order Monitoring Compliance Acknowledgement

Dear Parviz Boodjeh,

Over the last several years, government agencies have increased efforts at enforcing regulations relating to DEA registrants. As a manufacturer, Actavis takes significant measures to ensure the integrity of the product supply-chain, especially where controlled substances are involved. One of our primary goals is to minimize any potential for diversion of such products. We are confident that you, as an important participant in the controlled substance supply chain, share this objective.

In order to help us meet our goal we are asking our customers to execute a compliance acknowledgement form, a copy of which is enclosed. As you will see, by executing this form your organization represents it is aware of its obligations under federal and state statutes and regulations pertaining to the distribution of controlled substances, including 21 CFR 1301.74(b), and that it has in place measures to ensure compliance with such regulations. Please execute this acknowledgment and return it in the enclosed, self-addressed, stamped envelope within 30 days of the date of this letter. By executing this acknowledgement, you are not only affirming your own organization's commitment to fulfill its duties, you are helping Actavis do the same.

Together, we can better protect the supply chain while simultaneously ensuring that we continue to provide consumers with low cost medications they need.

Sincerely,



Michael R. Clarke
Ethics & Compliance Officer, Americas

cc: Lisa Pehlke
Alana Dundas
Jill Strang

Actavis US Headquarters
60 Columbia Road, Building B
Morristown, NJ 07960

973 993 4500
973-993-4303

www.actavis.com

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

ALLERGAN MDL 03382701

P-02399 _ 00002

COMPLIANCE ACKNOWLEDGEMENT FORM

Discount Drug Mart on behalf of itself and all of its subsidiaries, facilities or other locations registered to distribute controlled substances ("Customer"), acknowledges that it will abide by all applicable laws, rules, regulations, and any other regulatory and legal requirements of the U.S. Drug Enforcement Administration (DEA), the Food and Drug Administration (FDA), and of all states in which it distributes and/or dispenses controlled substances and of all states in which it is licensed. Further, Customer acknowledges that it will not distribute or dispense controlled substances if it suspects that a prescription has not been issued for a legitimate medical purpose or in the normal course of professional practice or if it determines that questions exist regarding the proper usage and/or adequate legal compliance by its customer.

Customer understands that Actavis is required by DEA regulations to report to the local DEA Diversion field office any instances of suspicious orders of controlled substances pursuant to DEA guidelines. To this end, Customer will provide to Actavis any information regarding Customer's distribution of controlled substances which Actavis may need to evaluate compliance with DEA regulations. Actavis reserves the right in all cases to limit or eliminate any sales of controlled substances to customers in any situation which it determines in its sole discretion poses issues or questions of proper usage and/or adequate legal compliance by the Customer.

Customer represents that directly monitors and remains aware of the proper usage and handling of controlled drugs that it distributes and/or dispenses and to exercise due diligence to ensure that its customers adhere to all applicable laws and regulatory requirements. Customer is expected to exercise its professional knowledge and expertise to keep current on all such legal and regulatory guidelines.

Customer acknowledges that Actavis may provide a copy of this agreement to the DEA, other federal regulatory agencies, state regulatory agencies, or state licensing boards when determined to be appropriate.

Customer agrees that failure to comply with this Agreement may result in the termination of the relationship between Actavis and Customer, in whole or in part, notwithstanding any other agreements to the contrary.

Agreed to by a duly authorized officer, partner, or principal of Customer.

Signature: 
Full Name (print): Tom Nameth
Title: Director of Pharmacy
Date: 10/11/2012